Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | LATS1 | O95835 | 11/20 | 0.43 |
| ▸ | LATS2 | Q9NRM7 | 8/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | KDM4A | O75164 | 1/20 | 0.38 |
| ▸ | KDM5C | P41229 | 1/20 | 0.38 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL246231 | 0.82 | LATS1 (0.43) | LATS1LATS2IDO1ACHEKDM4E | |
| SCHEMBL18266942 | 0.81 | CYP1A2 (0.57) | LATS1LATS2POLBACHEKDM4E | |
| SCHEMBL24174998 | 0.78 | NCF1 (0.59) | LMNALATS1LATS2POLBNR4A2 | |
| SCHEMBL6636067 | 0.78 | CDC7 (0.44) | LATS1LATS2L3MBTL1IDO1KDM4E | |
| SCHEMBL20574275 | 0.75 | LATS1 (0.56) | LATS1LATS2 | |
| SCHEMBL21173380 | 0.75 | LATS1 (0.41) | LATS1LATS2KDM4C | |
| SCHEMBL12653338 | 0.75 | TERT (0.50) | LATS1LATS2L3MBTL1 | |
| SCHEMBL20547705 | 0.75 | HIPK2 (0.42) | LATS1LATS2IDO1KDM4EKDM4A | |
| SCHEMBL30824509 | 0.75 | MAPT (0.67) | LMNAMAPTL3MBTL1KDM4E | |
| SCHEMBL318704 | 0.75 | MAPT (0.67) | LMNAMAPTL3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376099-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | NOVARTIS AG (CH) | 2024-11-14 | — | — | US | disclosed |
| CN-115215886-B | Compounds and compositions as endosomal Toll-like receptor inhibitors | 诺华股份有限公司 | 2024-10-11 | — | — | CN | disclosed |
| CN-115215886-A | Compounds and compositions as endosomal Toll-like receptor inhibitors | 诺华股份有限公司 | 2022-10-21 | — | — | CN | disclosed |
| EP-4059934-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | Novartis AG (CH) | 2022-09-21 | — | — | EP | disclosed |
| CN-109641899-B | Compounds and compositions as endosomal Toll-like receptor inhibitors | 诺华股份有限公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-3510033-B1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | NOVARTIS AG (CH) | 2021-11-24 | — | — | EP | disclosed |
| EP-3510033-B1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | NOVARTIS AG (CH) | 2021-11-24 | — | — | EP | disclosed |
| US-20210101902-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | NOVARTIS AG (CH) | 2021-04-08 | — | — | US | disclosed |
| US-20210101902-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | NOVARTIS AG (CH) | 2021-04-08 | — | — | US | disclosed |
| US-10954233-B2 | Compounds and compositions as inhibitors of endosomal toll-like receptors | NOVARTIS AG (CH) | 2021-03-23 | — | — | US | disclosed |
| US-10954233-B2 | Compounds and compositions as inhibitors of endosomal toll-like receptors | NOVARTIS AG (CH) | 2021-03-23 | — | — | US | disclosed |
| EP-3510033-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | Novartis AG (CH) | 2019-07-17 | — | — | EP | disclosed |
| US-20190211009-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. | 2019-07-11 | — | — | US | disclosed |
| US-20190211009-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. | 2019-07-11 | — | — | US | disclosed |
| CN-109641899-A | Compounds and compositions as endosomal Toll-like receptor inhibitors | 诺华股份有限公司 | 2019-04-16 | — | — | CN | disclosed |
| WO-2018047081-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | NOVARTIS AG (CH) | 2018-03-15 | — | — | WO | disclosed |
| WO-2018047081-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | NOVARTIS AG (CH) | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376099-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | TLR3, TLR1, TLR4 | LMNA 2514/4885MAPT 2938/4885LATS1 4114/4885 |
| US-20210101902-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | TLR3, TLR1, TLR4 | LMNA 2514/4885MAPT 2938/4885LATS1 4114/4885 |
| US-20190211009-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | TLR3, TLR1, TLR4 | LMNA 2514/4885MAPT 2938/4885LATS1 4114/4885 |
| US-10954233-B2 | Compounds and compositions as inhibitors of endosomal toll-like receptors | TLR3, TLR1, TLR4 | LMNA 2514/4885MAPT 2938/4885LATS1 4114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.